Innovate Pharmaceuticals seeks licensing partner for 'truly stable' liquid aspirin
UK firm worked with Croda for five years to develop the product
Innovate Pharmaceuticals, a privately held UK company, has developed what it claims is the world’s first ‘shelf stable’ liquid aspirin and is seeking a global licensing partner.
Innovate worked with chemicals company Croda International for five years on developing the product. The firm says other versions of so-called soluble aspirin are generally unstable suspensions containing particulate matter, which cause gastric irritation. But Innovate’s product is 'a true solution devoid of any particulate matter which is known to cause gastric irritation'.
Innovate’s CMO, consultant physician Dr Jimmy Stuart, said: ‘This is the realisation of five years of very hard work. What we have developed some would regard as the ‘holy grail’ of aspirin research. We want to get this product to the market as soon as possible so that many millions of patients can experience its benefits.’
Chief Executive Simon Cohen added: ‘'A significant proportion of potential aspirin users cannot tolerate its gastric side effects.
'Liquid aspirin will become the natural choice for this group and our product, as the only truly stable liquid aspirin, when commercialised, represents a US$500m-a-year business to any potential licensing partner, with only a modest 15–20% of the addressable market.’
